Study Reveals Tislelizumab’s Efficacy and Safety in uHCC Treatment
A recent study published in JAMA Oncology has shed light on the potential of tislelizumab as a first-line therapy for patients with unresectable hepatocellular carcinoma (uHCC). The study, known as RATIONALE-301, aimed to assess the efficacy and safety of tislelizumab in comparison to sorafenib tosylate.
HCN Medical Memo
This study reinforces the potential of tislelizumab as a first-line treatment option for patients with unresectable HCC. Healthcare professionals should consider these findings when making treatment decisions for their patients with uHCC in the future.
- The RATIONALE-301 study was an open-label, global, randomized, multiregional, phase 3 trial.
- It enrolled 674 systemic therapy-naive adults with histologically confirmed uHCC.
- Participants were randomized to receive either tislelizumab 200 mg intravenously every 3 weeks or sorafenib tosylate 400 mg orally twice daily.
- The primary endpoint was overall survival (OS), with secondary outcomes including objective response rate (ORR), progression-free survival, duration of response, and safety.
- Tislelizumab met the primary endpoint of OS noninferiority versus sorafenib in the intention-to-treat population.
- Tislelizumab demonstrated a higher ORR and a higher median duration of response.
Hepatocellular carcinoma is the most common type of primary liver cancer, accounting for about 75% of all liver cancers.
More on Liver Cancer